Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
about
The gut hormones in appetite regulationDrugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitisGlucagon-like peptide analogues for type 2 diabetes mellitusDrugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitisExenatide (Byetta) as a novel treatment option for type 2 diabetes mellitusMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesOne-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trialRegulatory challenges for new drugs to treat obesity and comorbid metabolic disordersMechanisms of action of glucagon-like peptide 1 in the pancreasCardiovascular safety of anti-diabetic drugsGlucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and futureA Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes MellitusThe GLP-1 agonist, liraglutide, as a pharmacotherapy for obesityTreatment of prediabetesAdvances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert ForumA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyondAdverse Effects of GLP-1 Receptor AgonistsIncretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseAvoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetesObesity pharmacotherapy: current perspectives and future directionsAssessment of pancreatic β-cell function: review of methods and clinical applicationsParkinson's disease, insulin resistance and novel agents of neuroprotectionGLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependenceDulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetesImpact of postprandial glycaemia on health and prevention of diseaseTreating the elderly diabetic patient: special considerationsCombining incretin-based therapies with insulin: realizing the potential in type 2 diabetesEffects of GLP-1 on appetite and weightA continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activitiesEffectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic PatientsGlucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndromeUpdate on the treatment of type 2 diabetes mellitusThe Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic ReviewEfficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitusEvaluating and treating cardiometabolic risk factors: a case discussionGut hormones and the regulation of energy homeostasisComparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysisNutrient-driven incretin secretion into intestinal lymph is different between diabetic Goto-Kakizaki rats and Wistar ratsCardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetesPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
P2860
Q21296779-7BFCFFDF-D8AE-4F1A-9309-4BBF8EFB0349Q24197984-2BF5CBCD-4C5A-4421-A787-39DC2978223DQ24243685-7FE403FE-E39D-42BD-98AF-7045108FB232Q24246447-CD1571CF-76C1-42A7-923F-70E7F7AAA831Q24548814-440D84F9-8D13-4710-8747-E87DB86696E0Q24642503-BB9188EF-92FC-46DA-9E69-D7DE13690D9FQ24656644-C32F942A-D17E-4C9F-AF40-CFDB0E591831Q24658031-04BE4EDE-B198-4631-B055-D6317ED784FEQ24683764-EA4B1A5D-EAD1-4CF1-AC63-5CE4A818666CQ26741082-CE7D82BB-1964-45EC-810F-0B6440004508Q26752699-B21A3B18-EE20-4214-9482-3E24AB06E431Q26765155-20EA33B5-49DC-49CB-AF71-BD03C08A3F7EQ26765609-6EF7499C-4B0E-48BB-A922-25F0ACA22A20Q26783350-89F118F6-BE84-44F5-ACC4-6AE1307B3A49Q26784022-B7E0495B-5B19-4CC9-8FE2-46EFCA820B3AQ26799389-3048F208-85C1-4EC4-9BC6-C046A43B9236Q26801346-53B75BED-0453-4B2D-BD95-612130EC6715Q26827183-BAAF2DA8-63DD-40C1-95E5-CCD7D024C1E7Q26827955-5F058D8A-07CF-4DDB-B0EA-7AEB362BB0F1Q26828559-AF93C511-AFDC-4C6B-9554-5C69E2095881Q26829445-BB004EDD-27EC-42B0-A64A-0CF601F8434FQ26853311-54374D85-50CE-4660-855D-F5FEF9152355Q26858990-4511CAA9-A488-4544-9A70-4EF4A194FF2CQ26861768-783B5C97-0912-4263-967B-105BD521295AQ26862823-0A6CD670-1FA7-457D-80F0-EA29FDF5ADE7Q26995176-4DB44567-D9C7-4D56-B089-0C8E1AC4F5AAQ27004723-06E20FB9-E710-42D8-8D80-C6626CEEC01FQ27011627-602651C4-202F-44CC-97E8-CEBF158C5C95Q27027240-76CDD329-D158-447E-B683-A66ED127E8B3Q28067209-A9D05EC6-BE07-4266-9F6C-E044A1DAB1D9Q28070416-6DA49ACE-6E6E-424C-B373-84B5ED3317BBQ28073342-488F6FD1-3F2C-492E-85AF-1C09C3E7CBC8Q28078225-A0F5F2BE-0A57-4DE8-9121-84D9DFB572AAQ28088578-88F2220B-15CF-4CD3-B3CE-132374FF5E11Q28196750-D15DD112-D195-4241-8CF6-8CC11A30C5C2Q28278826-D8F802CE-320E-4BF5-AC97-313BD5383A3CQ28546797-F230D318-16D6-43BE-8CC9-B277057F419AQ28564632-B8A945DC-7C6C-419E-BC8F-A5E0E2FBD3D9Q28741419-4935DB46-28A1-48D1-9ECD-FE1F8C1E8FA4Q30249371-FB34786C-DECC-444F-8442-67B277617C3B
P2860
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Effects of exenatide (exendin- ...... patients with type 2 diabetes.
@en
Effects of exenatide
@nl
type
label
Effects of exenatide (exendin- ...... patients with type 2 diabetes.
@en
Effects of exenatide
@nl
prefLabel
Effects of exenatide (exendin- ...... patients with type 2 diabetes.
@en
Effects of exenatide
@nl
P2093
P1433
P1476
Effects of exenatide (exendin- ...... patients with type 2 diabetes.
@en
P2093
Alain D Baron
Dennis D Kim
Mark S Fineman
Robert E Ratner
P304
P356
10.2337/DIACARE.28.5.1092
P407
P577
2005-05-01T00:00:00Z